S. 1339 · 119th Congress · International Affairs
Stop CCP Money Laundering Act of 2025
- IntroducedApr 8, 2025 Done
- CommitteeReferred to Banking, Housing, and Urban Affairs Current stage
- Senate floorNot yet Not reached yet
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
Full text
No CRS summary yet · 444 wordsS. 1339 · Introduced in Senate · Apr 8, 2025
This Act may be cited as the Stop Corrupt Communist Party Money Laundering Act of 2025 or the Stop CCP Money Laundering Act of 2025 .
(a) Determination with respect to money laundering. Not later than 180 days after the date of the enactment of this Act, the Secretary of the Treasury shall submit to the appropriate congressional committees a determination, including a detailed justification, of whether reasonable grounds exist for designating the Hong Kong Special Administrative Region of the People's Republic of China as a jurisdiction of primary money laundering concern under section 5318A of title 31, United States Code.
(b) Report on role of Hong Kong in export control and sanctions violations. (1) In general Not later than 360 days after the date of the enactment of this Act, the Secretary of State, in coordination with the Secretary of the Treasury and the Secretary of Commerce, shall submit to the appropriate congressional committees a report assessing the ability of United States and foreign financial institutions operating in Hong Kong to identify and prevent transactions that facilitate the transfer of products, technology, and money to the Russian Federation, Iran, and other countries and entities in violation of export controls and sanctions imposed by the United States. (2) Elements The report required by paragraph (1) shall include— (A) an evaluation of the extent of the role of Hong Kong as an international financial and trading center in facilitating, knowingly or unknowingly— (i) the transfer of products and technologies to adversaries of the United States, including the Russian Federation, Iran, the mainland of the People’s Republic of China, and other countries in violation of export controls imposed by the United States; and (ii) trade and financial transactions that violate sanctions imposed by the United States on the Russian Federation, Iran, and other countries and entities; (B) an assessment of whether the People’s Republic of China’s 2020 National Security Law and the January 2024 Safeguarding National Security Ordinance of Hong Kong have limited the ability of financial institutions operating in Hong Kong to adhere to global standards for anti-money laundering and know-your-customer procedures; and (C) a description of cooperation between Hong Kong and United States authorities in enforcing export control and sanctions regimes, including any challenges to such cooperation.
(c) Appropriate congressional committees defined. In this section, the term appropriate congressional committees means— (1) the Committee on Foreign Relations and the Committee on Banking, Housing, and Urban Affairs of the Senate; and (2) the Committee on Foreign Affairs and the Committee on Financial Services of the House of Representatives.
Shown here because the text is under 500 words. Open on Congress.gov
Who lobbies on it
9 organizations · 28 filings · Q2 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Sanofi Us Services Inc
6 of 6 quarters
“340B; Biologic/Small molecule drug negotiation eligibility within HR 7174/S.832 EPIC Act; CDC Type 1 Diabetes Awareness and Education within LHHS appropriations; Clinical Trial Diversity; Clinical Trial Data Requirements; Copay Accumulators; COPD Education and Awareness within LHHS appropriations; COPD Research…”
-
Merck & Co Inc
5 of 6 quarters
“S. 1339, Pharmacy Benefit Manager Reform Act S. 2076, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance (PASTEUR) Act of 2021 Issues relating to, 340B program integrity; 340B of the Public Health Services Act; 340B issues; 340B drug pricing program; Drug pricing; Drug pricing and reimbursement issues…”
-
Unitedhealth Group, Inc.
4 of 6 quarters
“Issues related to pharmacy benefit management, including in H.R. 5378 (Lower Costs, More Transparency Act), S.2973 (Modernizing and Ensuring PBM Accountability Act), S.1339 (Pharmacy Benefit Manager Reform Act), and H.R.10545 (American Relief Act, 2025).”
6 more organizations, every filingPROUpgrade
Organizations that named S. 1339 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
2 actions · newest first- Apr 8, 2025Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
- Apr 8, 2025Introduced in Senate